Last reviewed · How we verify
Remifentanyl, Ultiva®
Remifentanyl, Ultiva® is a Opioid agonist Small molecule drug developed by Fundación Universitaria de Ciencias de la Salud. It is currently FDA-approved for Intraoperative analgesia during general anesthesia, Sedation and analgesia in mechanically ventilated patients in intensive care settings.
Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation.
Remifentanil is a potent synthetic opioid agonist that binds to mu (μ) opioid receptors in the central nervous system to produce rapid analgesia and sedation. Used for Intraoperative analgesia during general anesthesia, Sedation and analgesia in mechanically ventilated patients in intensive care settings.
At a glance
| Generic name | Remifentanyl, Ultiva® |
|---|---|
| Sponsor | Fundación Universitaria de Ciencias de la Salud |
| Drug class | Opioid agonist |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Remifentanil activates mu opioid receptors, which are G-protein coupled receptors involved in pain modulation and sedation. It has an extremely rapid onset (within 1-3 minutes) and offset (within 5-10 minutes after infusion cessation) due to rapid ester hydrolysis by non-specific plasma and tissue esterases, making it ideal for intraoperative use. Its short duration and predictable pharmacokinetics allow for precise titration during anesthesia.
Approved indications
- Intraoperative analgesia during general anesthesia
- Sedation and analgesia in mechanically ventilated patients in intensive care settings
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
- Nausea and vomiting
- Postoperative pain
Key clinical trials
- Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide (PHASE3)
- The Effect of Preoperative Maxigesic® on Intraoperative Remifentanil Requirement (NA)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Impact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation (NA)
- Impact of Interscalene Block Combined With General Anesthesia on Burst Suppression in Shoulder Surgery Patients (NA)
- Correlation Between Sedation Depth Monitoring and Reflexes During Intravenous Anesthesia With Dexmedetomidine and Remifentanil in Children Undergoing Direct Laryngoscopy for Surgical Procedures
- The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption (NA)
- Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanyl, Ultiva® CI brief — competitive landscape report
- Remifentanyl, Ultiva® updates RSS · CI watch RSS
- Fundación Universitaria de Ciencias de la Salud portfolio CI
Frequently asked questions about Remifentanyl, Ultiva®
What is Remifentanyl, Ultiva®?
How does Remifentanyl, Ultiva® work?
What is Remifentanyl, Ultiva® used for?
Who makes Remifentanyl, Ultiva®?
What drug class is Remifentanyl, Ultiva® in?
What development phase is Remifentanyl, Ultiva® in?
What are the side effects of Remifentanyl, Ultiva®?
What does Remifentanyl, Ultiva® target?
Related
- Drug class: All Opioid agonist drugs
- Target: All drugs targeting Mu (μ) opioid receptor
- Manufacturer: Fundación Universitaria de Ciencias de la Salud — full pipeline
- Therapeutic area: All drugs in Anesthesia
- Indication: Drugs for Intraoperative analgesia during general anesthesia
- Indication: Drugs for Sedation and analgesia in mechanically ventilated patients in intensive care settings
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing